genekam logo
  • usa
    • german
    • russia
    • china
Duissernstr. 65a · 47058 Duisburg · Germany
Tel. +49 203 / 555 858 -31 / 32 / 33 · Fax: +49 203 / 35 82 99
menuicon
slider
Latest News:

21.01.2020
Genekam has developed novel corona virus 2020 (Wuhan strain specific) kits and potential therapeutic molecules.

Latest News:

21.01.2020
3D Genomemedicine Inc is going to operate in USA

  • ++BREAKING NEWS (26.05.2020)++

    Plasma therapy accelerator (SARS-Hunter): a new solution for better antibody therapy for all coronavirus patients.

  • MEDICA 2021

    Visit us at MEDICA in Duesseldorf, Germany:
    15.11. - 18.11.21

  • BIO CEO & Investor Digital Conference

    Visit us at BIO CEO & Investor Digital Conference New York, USA:
    16.02. - 18.02.2021

  • INVEST 2021

    Visit us at INVEST in Stuttgart, Germany:
    23.03. - 24.04.21

  • LSX World Congress

    Visit us at LSX World Congress 2021 Virtual London, UK:
    01.02 - 05.02.2021

  • LSX Investival Showcase Virtual 2020

    Visit us at Investival Showcase Virtual London, UK:
    11.11. - 16.11.20

T-cell immunotherapy solution - car T-cell therapy

There are many laboratories developing CAR T-cell therapies. Genekam has a number of kits to develop CAR T-Cell therapy e.g. isolate large number of T cells (CD4 / CD8) from blood or other source. This isolation kit will generate larger number of needed T cells against number of cells generated through density gradient methods (also called Ficolle), Magnetic beads based Kits are for separation of wanted T cells from other unwanted cells. After that they can be stimulated or undergo the cloning with specific vectors carrying specific sequences. Genekam has developed a kit, which can remove the unwanted erythrocytes, which may be disturbing factors during the development. This can accelerate the development of CAR T-cells therapies against any possible target in field oncology, virology or transplantation medicine. These kits help to make therapies economically.
TOP